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ABSTRACT 37 
 38 
BACKGROUND 39 
Thyroid autoimmunity, especially Graves’ disease or hypothyroidism with positive 40 
autoantibodies (TRAb) to the thyrotropin receptor (TSHR), occurs in 30-40% of patients 41 
with relapsing multiple sclerosis (MS) following treatment with alemtuzumab (ALTZ). 42 
ALTZ therapy therefore provides a unique opportunity to study the evolution of TRAb 43 
prior to clinical presentation. TRAb can stimulate (TSAb), block (TBAb) or not affect 44 
(“neutral”: TNAb) the TSHR function, causing hyperthyroidism, hypothyroidism or 45 
euthyroidism, respectively. 46 
METHODS 47 
We conducted a longitudinal retrospective analysis of TRAb bioactivity over a period of 9 48 
years in 45 MS patients receiving ALTZ using available stored serum; 31 developed 49 
thyroid dysfunction (TD) and 14 remained euthyroid despite being followed for a 50 
minimum of 5 years (NO-TD). The presence of TRAb was evaluated at standardized time 51 
points: A) pre-ALTZ, B) latest time available post-ALTZ and before TD onset, C) post-52 
ALTZ during/after TD onset. Serum TRAb were detected by published in-house assays 53 
(ihTRAb): flow cytometry (FC) detecting any TSHR-binding TRAb and luciferase 54 
bioassays (LB) detecting TSAb/TBAb bioactivity. Purified IgGs were used to verify 55 
TSAb/TBAb in selected hypothyroid cases. Standard clinical automated measurements of 56 
TRAb (autTRAb), anti-thyroid peroxidase autoantibodies (TPOAb), thyroid stimulating 57 
hormone, free-thyroxine and free-triiodothyronine were also collected. 58 
RESULTS 59 
Pre-ALTZ, combined ihTRAb (positive with FC and/or LB), but not autTRAb, were 60 
present in 5/16 (31.2%) TD versus 0/14 (0%) NO-TD (p=0.017). Detectable ihTRAb 61 
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preceded TD development in 9/28 (32.1%) and by a median of 1.2 years (range 28 days – 62 
7.3 years). Combination testing of ihTRAb and TPOAb at baseline predicted 20% of 63 
subsequent cases of hyperthyroidism and 83% of hypothyroidism. 64 
CONCLUSIONS 65 
We present evidence that TRAb measured with custom-made assays can be detected prior 66 
to any change in thyroid function in up to a third of cases of ALTZ-related TD. 67 
Furthermore, The presence of ihTRAb prior to ALTZ treatment was strongly predictive of 68 
subsequent TD. Our findings suggest that a period of affinity maturation of TRAb may 69 
precede clinical disease onset in some cases. Combined testing of TPOAb and ihTRAb 70 
may increase our ability to predict those who will develop thyroid dysfunction post 71 
ALTZ.  72 
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INTRODUCTION 73 
Alemtuzumab (ALTZ; Campath-1H) is an anti-CD52 humanized monoclonal 74 
which has proven efficacy in relapsing multiple sclerosis (MS) (1). It is administered as a 75 
standard treatment regime (two cycles one year apart), with subsequent courses 76 
determined by evidence of returning central nervous system inflammatory activity. It 77 
causes rapid complement mediated lysis of circulating lymphocytes and profound 78 
lymphopenia. Since bone marrow derived lymphoid precursors are unaffected, 79 
lymphocyte reconstitution subsequently occurs, which appears to have a beneficial effect. 80 
Patterns of lymphocyte re-population vary between patients but circulating B cells return 81 
most rapidly and can rise to higher levels than baseline (2), whilst CD4/CD8 T cells 82 
numbers recover more slowly, and may never attain pre-treatment levels (3,4). Despite 83 
prolonged T cell lymphopenia post-alemtuzumab immune competence is largely 84 
preserved and significant infections occur only rarely (5). However 30-48% of patients 85 
develop secondary autoimmunity, mainly humoral, 0.5–11 years after treatment (peak 86 
incidence 2-3 years) (6-10). The commonest disease (41%) is thyroid autoimmunity (TA) 87 
(11), followed by idiopathic thrombocytopenic purpura (1-3%). However, a range of other 88 
rare autoimmune disorders including haemolytic anaemia, neutropenia and Goodpasture 89 
syndrome have also been reported (1,12-14). The exact pathogenic mechanism for post-90 
ALTZ TA remains unclear, however it is considered to be an “immune reconstitution 91 
syndrome”, i.e. an autoimmune phenomenon occurring during or after a phase of immune 92 
restoration following lymphopenia. This has also been reported in HIV patients following 93 
antiretroviral therapy and after bone marrow transplantation (7,8).  94 
Among TA, ALTZ predominantly induces Graves’ disease (GD: 63%), followed 95 
by hypothyroidism (34%), and rarely transient thyroiditis (11). GD is caused by anti-96 
thyrotropin (TSH) receptor (TSHR) autoantibodies (TRAb) persistently activating the 97 
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TSHR (TSHR-stimulating antibodies: TSAb), leading to hyperthyroidism (15). TRAb can 98 
also block the TSHR (TSHR-blocking antibodies, TBAb), causing hypothyroidism 99 
(16,17), and “neutral” TRAb (which bind the TSHR without affecting thyroid function: 100 
TNAb) have been reported in around 12% of subjects with normal thyroid function, 59-101 
84% GD patients (depending on the assay type used), and patients with autoimmune 102 
thyroiditis at lower rates (18-20). TNAb seem to bind TSHR but do not activate the 103 
cAMP signaling cascade, which is the principal pathway leading to thyroid hormones 104 
synthesis; however they may be able to trigger alternative and multiple signaling cascades 105 
having complex downstream effects, including oxidative stress (20). 106 
In spontaneous TA, TBAb account for a minority of cases of hypothyroidism 107 
(around 9-10%) (16,21), the remainder being due to lymphocyte-mediated damaging of 108 
the thyroid, as in classical Hashimoto’s thyroiditis (22). Autoantibodies to thyroid 109 
peroxidase (TPOAb) are the hallmark of such autoimmune thyroiditis, however they are 110 
very often positive in GD also, indicating that in TA the self-tolerance breakdown 111 
involves multiple thyroid antigens (23). Surprisingly, TRAb are positive in 50.0%-76.7% 112 
of patients with post-ALTZ hypothyroidism (9,10), with TBAb representing a common 113 
mechanism of post-ALTZ hypothyroidism in a recent analysis (10).   114 
TPOAb are very common in the general population (up to 20%) (24,25), and have 115 
been identified as a predictive marker of TD subsequent to ALTZ (9). In particular, 69% 116 
of MS subjects TPOAb positive before ALTZ developed subsequent TD, compared to 117 
31% of TPOAb negative subjects. However, 85% patients who later developed TD were 118 
TPOAb negative at baseline, indicating that TPOAb status alone has limited value in risk 119 
stratification in the majority of patients (9).  120 
The longitudinal study of ALTZ-treated patients provides a rare opportunity to 121 
study TRAb prevalence and biological function prior to disease “triggering” in patients 122 
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who develop GD. The automated TRAb assays (autTRAb) used in clinical diagnostics are 123 
unable to distinguish TSAb/TBAb (26); as a result several groups including ours have 124 
developed in-house bioassays able to detect TSAb (27,28) and TBAb (21,29), as well as 125 
TNAb (19). We postulated that TRAb, in particular TNAb, pre-existing before ALTZ 126 
may be the precursors of the TSAb and TBAb that subsequently develop by somatic 127 
hypermutation and affinity maturation in B cells (30,31). Detection of low titre or low 128 
affinity TSAb/TBAb or the presence of TNAb prior to ALTZ therapy, in combination 129 
with TPOAb testing, may also increase our ability to predict thyroid dysfunction after 130 
ALTZ. 131 
In addition we used the in-house TRAb bioassays (ihTRAb) to analyze TRAb 132 
bioactivity arising after ALTZ therapy, which has so far only been described in 133 
spontaneous TA (21,28,32). In a recent UK study conducted in collaboration between 134 
Cambridge and Cardiff we have introduced TSAb/TBAb analysis in post-ALTZ TA, 135 
however this was limited to only a few patients affected with hypothyroidism or 136 
“fluctuating” GD, defined as multiple alternate phases of hyperthyroidism and 137 
hypothyroidism (10). In the present study we extended this analysis to all available cases, 138 
including a third different in-house assay to detect TSHR-binding TRAb independently 139 
from their bioactivity (19). 140 
MATERIALS AND METHODS 141 
Patients and sera 142 
Blood samples from Welsh MS patients consenting to research have been 143 
consecutively collected for research purposes from 2006 (REC# 05/WSE03/111), and 144 
stored within the Welsh Neuroscience Research Tissue Bank (WNRTB: Cardiff, UK, 145 
REC# 14/WA/0073). Blood samples were processed within 3 hours of collection 146 
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following a standardized protocol including spin at 4500 rpm for 10 minutes at +4°C. 147 
Serum and plasma were subsequently aliquoted and stored at -80°C. 148 
Sera of 45 patients affected with relapsing MS treated with ALTZ with 149 
longitudinal samples between August 2006 to October 2015 were identified including 150 
samples from 31 consecutive subjects with post-ALTZ thyroid dysfunction (TD). 151 
Samples from 14 patients who had not developed TD (NO-TD) were also selected based 152 
on the availability of serum before ALTZ, and clinical follow-up of ≥5 years, in order to 153 
exclude cases of late TD onset (11). Sera from pre-specified time-points were requested 154 
for TD and NO-TD groups (Figure 1): A) first available pre-ALTZ time; B) the latest time 155 
available post-ALTZ and before the TD onset; C) post-ALTZ at the TD onset, or 156 
alternatively the earliest subsequent time available (TD only).  157 
All patients were treated with ALTZ at the University Hospital of Wales (UHW) 158 
in Cardiff, UK, and followed up both at UHW and local Welsh hospitals. ALTZ was 159 
administered intravenously 5 consecutive days for the first cycle, with the majority of 160 
subjects receiving a second cycle (3 consecutive days) 12 months later; in some patients 161 
further doses were given at least one year apart, depending on clinical and radiological 162 
outcomes. The date of the first ALTZ administration within our patient cohort ranged 163 
from April 2002 to November 2012; the initiation dose was 24-30 mg/day prior to 2006, 164 
then reduced to 12 mg/day. Since blood collection for research purposes commenced only 165 
in 2006, this explains why time-point A is missing in several patients. 166 
Information about patients’ age, TSH, free-thyroxine (FT4), free-triiodothyronine 167 
(FT3), TPOAb, TRAb determined by automated assays, thyroid treatment, and number of 168 
ALTZ treatments were collected, when available. Demographic information and detailed 169 
longitudinal clinical information was available for all patients, with last update in 170 
February 2018. 171 
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Luciferase bioassays (TSAb/TBAb) 172 
In-house luciferase bioassays (LB) to detect TSAb and TBAb were performed 173 
using a Chinese Hamster Ovary (CHO) cell line stably transfected with the human TSHR 174 
and a cAMP responsive luciferase reporter (pA3Luc), as previously described (Lulu*) 175 
(27,29). Briefly, cells were seeded at 2x104 cells/well in 96-well plates in Ham's F12 176 
containing 10% fetal calf serum, and switched to Ham's F12 containing 10% charcoal 177 
stripped calf serum the day before the assay. In the assays cells were incubated for 4 hours 178 
at 37°C in 5% CO2 in air with whole human serum (1:10 dilution) in serum-free medium 179 
(SFM: Ham’s F-12 supplemented with 2.5% sodium bicarbonate) for the TSAb assay, and 180 
SFM containing 1 mU/ml bovine TSH (bTSH; Sigma-Aldrich Company Ltd., Poole, UK) 181 
in the TBAb assay. Cells were also incubated with SFM alone as negative control, and 5 182 
mU/ml bTSH and 0.2 ng/μl M22 human monoclonal Ab to TSHR (RSR, Cardiff, UK) as 183 
positive controls. Cells were finally lysed, and the luciferase activity measured using 184 
commercially available kits (Promega, Madison, USA) and a luminometer machine 185 
(Glomax®-Multi Detection System, Promega). 186 
Randomly selected sera from 9 euthyroid participants from the Controlled 187 
Antenatal Thyroid Screening II (CATS II) study (33,34) were used as euthyroid pool in 188 
both TSAb/TBAb assays; they were all adult women (mean age ± standard deviation = 189 
40.8 ± 5.3 years) with normal thyroid function and negative for TPOAb.  190 
In the TSAb assay, CHO cells transfected with pA3Luc only (Zulu) were used in 191 
parallel to Lulu*. The considered positivity cut-off was a stimulation index (SI) >1.5 192 
calculated with the following formula:  193 
SI =   light patient sample Lulu* / light patient sample Zulu 194 
                     light euthyroid pool Lulu* / light euthyroid pool Zulu 195 
 196 
The TBAb assay positivity cut-off was an inhibition index (InI) >20% as 197 
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previously determined (formula A) (29) using Lulu* cultured with 1 mU/ml bTSH: 198 
InI = 100 X (1 – light patient sample) 199 
                                     light euthyroid pool  200 
In order to exclude interference of high serum TSH levels with our in-house 201 
TSAb/TBAb serum assay, especially among hypothyroid patients, experiments were 202 
repeated using IgG (amount equivalent to 1:10 serum dilution) in place of serum; if 203 
results were discordant we counted those using IgGs. IgGs were purified from selected 204 
serum samples with the Melon Gel IgG Purification Kit (Pierce, Rockford, IL) according 205 
to the manufacturer’s protocol. Briefly, serum samples were diluted 1:10 and the diluted 206 
serum was added to a spin column containing the Melon Gel resin. After 30 minutes 207 
incubation, the purified IgGs were collected in the flow through by centrifugation of the 208 
spin column, and the IgG concentration measured by ultraviolet optical absorption at 280 209 
nm with a NanoDropTM Lite spectrophotometer (Thermo Scientific). All IgG purified 210 
samples were promptly used for downstream analysis, or aliquoted and stored at -20 °C. 211 
Flow Cytometry (TSHR-binding TRAb) 212 
In order to reduce the high non-specific background staining due to human 213 
antibodies recognizing and/or cross-binding to surface CHO proteins, a serum pre-214 
adsorption step using Zulu cells was performed as previously described (35). 215 
Flow cytometry (FC) detection of TSHR-binding TRAb (FC-TRAb) in pre-216 
adsorbed sera was then performed using CHO cells expressing the 217 
glycosylphosphatidylinositol (GPI)-anchored TSHR extracellular domain (CHO-TSHR), 218 
as previously described (19). As minor protocol modifications, 1:100 goat polyclonal anti-219 
human IgG (H+L) Alexa Fluor 488 (Life Technologies) and 1:1000 LIVE/DEAD® 220 
Fixable Near-IR Dead Cell Stain Kit (Invitrogen) were used as second conjugated-221 
antibody and viability dye, respectively (35). Zulu cells were used as CHO control cell 222 
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line not expressing TSHR. The fluorescence of 10,000 cells/tube was assayed by BD 223 
FACSCanto II flow cytofluorometer, FACSDiva Software (BD Biosciences, San Jose, 224 
USA); no FITC (TRAb) and Apc-Cy7 (LIVE/DEAD®) channels compensation was 225 
needed (500-520 nm and 633-750 nm excitation-emission peaks wavelengths 226 
respectively)(35).  227 
Flow Cytometric data were analyzed using FlowJo 8.8.6 Software (TreeStar Inc., 228 
Ashland, USA), and damaged or dead cells (Apc-Cy7 positive) gated and excluded from 229 
analysis (35). The geometric mean FITC fluorescence intensity values of CHO-TSHR and 230 
Zulu cells were compared for all sera and the Kolmogorov–Smirnov univariate two-231 
sample test was used to obtain the greatest difference between the two histograms, quoted 232 
as D value (D) (36). Cut-off values were defined based on the mean D +2 SD of 233 
individual pre-adsorbed sera from 9 healthy women from the CATS II study (33,34) used 234 
as controls; all values higher than this were considered positive (FC-TRAb+) (35). 235 
Automated Laboratory Measurements 236 
Automated TRAb (autTRAb) were measured with the Brahms Diagnostika 237 
Lumitest TRAK assay  (Germany; Reference Ranges IU/L = Negative <1, Borderline 1–238 
1.5, Positive >1.5) until January 2014, then using the Roche Cobas® e411 assay 239 
(Switzerland; Reference Ranges IU/L = Negative <0.9, Borderline 0.9–1.6, Positive 240 
>1.6). According to Thermoscientific, human TSH does not interfere with TRAb 241 
measurement in the Lumitest TRAK assay, up to TSH values of at least 500mU/L. UHW 242 
Biochemistry Department also run specific cross-reactivity tests using patient serum with 243 
a TSH concentration of 179 mU/L, confirming no interference with neither Brahms nor 244 
Roche TRAb assays. 245 
TPOAb, TSH, FT4 and FT3 analyses were performed using an ADVIA Centaur 246 
automated immunoassay analyser (Bayer plc, UK) until 31/05/2010, followed by 247 
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Chemiluminescent Microparticle Immunoassay methods by the ARCHITECT® System 248 
(ABBOTT Laboratories, USA) until the end of the observation period. Supplemental 249 
Table 1 summarizes the changes of reference ranges occurred during this time period. 250 
Definitions of Thyroid Function 251 
All 45 patients included in the study were euthyroid when receiving the first 252 
ALTZ treatment, and had no clinical history of thyroid disease. The time of TD onset was 253 
defined as the first alteration of the thyroid function defined as persistent (i.e. detectable 254 
in consecutive blood tests at least 3 months apart) and/or significant (i.e. requiring 255 
immediate thyroid treatment). Hyperthyroidism was defined as low TSH with or without 256 
raised FT4/FT3 levels; hypothyroidism was defined as raised TSH with or without low 257 
FT4/FT3 levels. 258 
Thyroid diagnosis was defined as:  259 
I) GD: TRAb+ hyperthyroidism 260 
II) Fluctuating GD: TRAb+ cases with multiple alternate phases of hyperthyroidism and 261 
hypothyroidism, not explained by overtreatment or poor treatment compliance 262 
III) TRAb+ hypothyroidism 263 
IV) Chronic autoimmune thyroiditis (37): persistent hypothyroidism (≥ 6 months) with 264 
positive TPOAb and negative TRAb  265 
V) Subacute thyroiditis: transient hyperthyroidism, hypothyroidism or both with TD 266 
lasting in total <6 months, TRAb negative, with or without TPOAb 267 
VI) TPOAb-/TRAb- hypothyroidism: persistent hypothyroidism (≥ 6 months) with 268 
negative TPOAb and TRAb 269 
Statistical Analysis 270 
According to the TRAb prevalence in the general population of 12% (19), our a 271 
priori power calculation indicated 12 versus 12 subjects required to provide 80% power to 272 
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detect a 5-fold TRAb prevalence (60%) in patients that will later develop ALTZ-induced 273 
thyroid dysfunction, with a 0.05 significance level (two-tailed). 274 
Presence of TRAb at different time-points was compared between TD and NO-TD 275 
groups using the Fisher Exact Text, considering p<0.05 as significance level. As 276 
explorative analysis, positivity of TPOAb and TRAb measured with automated assays 277 
was also considered. 278 
Fisher exact test and t-test were used also to compare the characteristics of TD and 279 
NO-TD groups, considering p<0.05 as significance level. 280 
RESULTS 281 
Patients 282 
The date of first ALTZ treatment ranged from 2002 to 2012 (median 2008), and 283 
the mean ± SD follow-up was 9.0 ± 2.5 years post-ALTZ (range: 4.3 – 14.0 years). The 284 
TD group comprised patients showing post-ALTZ hyperthyroidism (n=19) or 285 
hypothyroidism (n=12) as first clinical manifestation (TD onset). 286 
Table 1 summarizes the characteristics of TD and NO-TD groups; no significant 287 
differences were detected between the different groups. Before TD onset (time-points A 288 
and B) all patients were euthyroid and free of persistent thyroid function abnormalities. 289 
Note that at time-point C (TD group) many patients who developed thyroid dysfunction 290 
were already on thyroid medication: a detailed description of their treatments and 291 
outcomes has been reported elsewhere (10). 292 
Combined in-house TRAb (ihTRAb) results at all time-points  293 
We compared the overall results obtained with the three different ihTRAb assays 294 
(FC-TRAb, LB-TSAb, LB-TBAb) at all time-points in TD and NO-TD groups. Due to the 295 
retrospective nature of this study, sera from some time-points were unavailable for the TD 296 
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group (Table 1). As shown in Figure 2, at time-point A (before ALTZ) 5/16 (31.2%) TD 297 
patients were found to be ihTRAb positive (ihTRAb+), compared with 0/14 (0%) NO-TD 298 
patients (p=0.017). Following ALTZ, 6/25 (24.0%) TD patients were ihTRAb+ at time-299 
point B (before TD onset); as expected, at time-point C (during or after TD onset) 300 
ihTRAb+ cases markedly increased to 18/29 (62.1%). This prevalence is likely to be 301 
underestimated, considering the late average collection time of time-point C compared 302 
with disease onset (Table 1). Among NO-TD patients, 4/14 (28.6%) were ihTRAb+ at 303 
time-point B. When splitting the overall ihTRAb+ results according to the TD subtype at 304 
onset (hyperthyroidism or hypothyroidism), time-point A ihTRAb were predominantly 305 
positive in those who subsequently developed hypothyroidism (4/6: 66.7%) rather than 306 
hyperthyroidism (1/10: 10%), p=0.036. It is worth noting that two initially hypothyroid 307 
ihTRAb+ patients subsequently showed a fluctuating thyroid function and were classified 308 
as fluctuating GD.  309 
Time-point A: predictors of post-ALTZ TD 310 
To validate TRAb as an independent predictor of ALTZ-induced TD, we 311 
compared ihTRAb results with autTRAb and TPOAb data at time-point A (Table 2). Pre-312 
ALTZ ihTRAb and TPOAb had a very similar predictive value for future TD 313 
development. When ihTRAb and TPOAb testing were combined together, 7/16 (43.8%) 314 
TD patients were positive, versus 0/14 of NO-TD group (p=0.007); in particular 83.3% 315 
hypothyroid and 20% hyperthyroid cases were predicted, versus 50% and 20% 316 
respectively when considering TPOAb alone (Table 2, last two columns). Detailed TRAb 317 
and/or TPOAb predictive values, sensitivity and specificity have been reported in 318 
supplemental Table 2. 319 
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Considering this from a different perspective, TD developed in 7/7 (100%) 320 
baseline ihTRAb and/or TPOAb positive patients, versus 9/23 (39.1%) baseline ihTRAb 321 
and/or TPOAb negative patients (p=0.007). 322 
AutTRAb were positive before ALTZ in only 1 patient of the TD hyperthyroid 323 
subgroup (14.3%) and none in the hypothyroid group, suggesting that autTRAb do not 324 
appear to be a useful predictive marker of subsequent TD development. 325 
In depth analysis of ihTRAb+ cases 326 
Table 3 reports in more detail the ihTRAb+ cases only, describing the different 327 
ihTRAb subtypes in comparison with autTRAb, TPOAb, and TSH results, when 328 
available. Here the hyperthyroid group was further subdivided into classic hyperthyroid 329 
GD and fluctuating GD. At time-point A ihTRAb+ cases as expected were predominantly 330 
TNAb (3/5: 60%), defined as FC-TRAb+ but both LB-TSAb/TBAb negative (Table 3).  331 
At time-point B, ihTRAb+ cases were represented by a similar proportion of 332 
TNAb, TSAb and TBAb (Table 3). In combination, TNAb or TSAb/TBAb preceded TD 333 
onset in 9 cases (32.1%, considering a total of 28 TD patients with time-point A and/or B 334 
available) with an interval before TD onset of a median of 1.2 years (range 28 days – 7.3 335 
years). 336 
At time-point C (Table 3), as expected all ihTRAb+ hyperthyroid GD and 337 
fluctuating GD patients were also autTRAb+, confirming a GD diagnosis. Among 338 
ihTRAb+ hyperthyroid and fluctuating GD cases, FC-TRAb was the most sensitive assay 339 
with 13/14 (92.9%) positive, versus 9/14 (64.3%) of TSAb. TBAb were positive in 3/10 340 
(30%) purely hyperthyroid ihTRAb+ GD patients. As expected fluctuating GD cases had 341 
a documented TSAb/TBAb coexistence in 2/4 (50%) cases (IDs 35, 42); the other two 342 
cases were positive for TSAb only (IDs 1, 7).  343 
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Among the whole hypothyroid group (n=10), 4 (40%) were ihTRAb+ at time-point C, in 344 
particular 2/4 (50%) FC-TRAb+ and 2/4 (50%) both FC-TRAb+ and TBAb+; autTRAb 345 
results were concordant (Table 3). Surprisingly, both ihTRAb+ hypothyroid patients at 346 
time-point A (IDs 15, 37) resulted ihTRAb negative at time-point C. 347 
Final thyroid diagnosis  348 
TPOAb titres measured anytime post-ALTZ were available in 17/19 (89.5%) of 349 
hyperthyroid group, and were positive in 15/17 (88.2%) cases; in fact two TPOAb 350 
negative GD patients at time-point C (Table 3) later became TPOAb positive, for example 351 
ID 27. Anytime post-ALTZ, TPOAb were positive in 11/12 (91.7%) of hypothyroid 352 
patients. None of the 14 NO-TD patients developed post-ALTZ TPOAb. 353 
According to their clinical course, TD patients were classified as pure 354 
hyperthyroid GD (n=17), fluctuating GD (n=4), and hypothyroid patients (n=10). 355 
AutTRAb were positive in 17/17 (100%) GD and 4/4 (100%) fluctuating GD. Taking our 356 
ihTRAb results into account to better define the final thyroid diagnosis among the 31 TD 357 
patients according to the criteria given in the methods identified 17 (54.8%) GD, 4 358 
(12.9%) fluctuating GD (2 started with hypothyroidism, 2 with hyperthyroidism), 4 359 
(12.9%) TRAb+ hypothyroidism, 3 (9.7%) chronic autoimmune thyroiditis, 2 (6.5%) 360 
TPOAb+ subacute thyroiditis, 1 (3.2%) TPOAb-/TRAb- hypothyroidism. 361 
DISCUSSION 362 
We have described for the first time the biological function of TRAb in a 363 
longitudinal cohort of patients developing ALTZ-induced thyroid dysfunction (TD) using 364 
three different in-house TRAb assays (ihTRAb). Importantly, as a result of a structured 365 
monitoring and sampling process for patients with MS in south Wales and suitable for 366 
ALTZ treatment, serum was available before the onset of TD enabling us to describe how 367 
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and when TRAb become positive in patients with ALTZ-induced TD. This setting is 368 
unique, as serum is not generally available before disease onset in sporadic GD. 369 
Interestingly, serum ihTRAb, but not TRAb detected with standard automated assays 370 
(autTRAb), were detected before ALTZ in one third of patients who later developed TD, 371 
and in none of those who remained free of TD (NO-TD) over a minimum follow-up 372 
period of 5 years. The appearance of ihTRAb was detected a mean of 1.2 years (range 28 373 
days – 7.3 years) prior to the development of thyroid dysfunction. We believe this is the 374 
first report of the detection of TRAb prior to the onset of ALTZ-induced TD. Similar 375 
findings have been previously described for spontaneous TD in a retrospective study 376 
showing progressively increasing TRAb positivity, as well as TPOAb and anti-377 
thyroglobulin antibodies, in patients who will later develop GD. In particular TRAb 378 
positivity increased from 2% at 7 years before diagnosis to 55% at diagnosis, with 379 
intermediate percentages of 7% and 20% at -5 and -2 years, respectively (38).  380 
Furthermore, in our study for the first time we provided details about TRAb 381 
biological function over time. We have previously reported the presence neutral TRAb 382 
(TNAb), detected using flow cytometry, in healthy euthyroid subjects, but without any 383 
follow-up clinical data to indicate whether they later did develop TD (19). Information 384 
similar to our data in ALTZ-induced disease are difficult to collect in the setting of 385 
spontaneous autoimmune TD, requiring very large and long-term cohort studies. The fact 386 
that the rates of TD post ALTZ are much higher than generally seen in MS, suggests that 387 
the two settings are not necessarily comparable, however the principle that autoimmunity 388 
to the TSHR may precede TD by many months or years applies to both ALTZ-induced 389 
(this study) and spontaneous forms as reported by others (38). Note that the wide range of 390 
pre-TD intervals (28 days – 7.3 years) is partly a consequence of the retrospective nature 391 
of this study, not providing systematic and identical time-points for all patients. Future 392 
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prospective studies are needed to precisely define how long ihTRAb may precede the 393 
onset of TD in some cases.  394 
In cases of TRAb positivity pre-dating TD, we hypothesize that TSHR-reactive B 395 
cell clones may undergo progressive antigen-driven affinity maturation by somatic 396 
hypermutation within germinal centres, and finally generate high affinity stimulating 397 
(TSAb) or blocking (TBAb) TRAb. The phenomenon of multiple different pathogenic 398 
TRAb arising from single B cell clones by somatic hypermutation has already been 399 
described in mouse models of GD (30,31). In this context, our finding that ihTRAb more 400 
commonly preceded hypo- than hyperthyroidism is interesting, but may reflect that once a 401 
stimulatory TSAb-secreting clone develops, TD follows rapidly whereas it may take 402 
longer for TBAb to achieve clinically relevant inhibition of thyroid function such that 403 
TSH levels rise. Our observations are in accordance with previous evidence that TSAb are 404 
potent at low concentrations, therefore inducing hyperthyroidism rapidly after their 405 
appearance (23), while TBAb levels needed to trigger hypothyroidism are usually much 406 
higher than TSAb levels inducing hyperthyroidism (26). Further prospective studies with 407 
large numbers of subjects should clarify this. It also has to be mentioned that we did not 408 
sub-classify TD patients into subclinical and overt disease since the vast majority of 409 
patients diagnosed with subclinical disease went on to develop overt thyroid dysfunction, 410 
or were treated immediately after diagnosis, preventing the possible evolution to overt 411 
disease.  412 
Although it is understandable that TNAb can exist without altering thyroid 413 
function, it is less clear how this is possible with TSAb and TBAb. Possible explanations 414 
for TSAb/TBAb positive cases in euthyroid patients are: i) they are low-affinity, therefore 415 
not able to exert a significant function on TSHR activity with clinical consequence; ii) the 416 
in vitro assays in some cases do not reflect the different and more complex human thyroid 417 
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environment, providing slightly different results from in vivo. For example luciferase 418 
bioassays use bovine and not human TSH, CHO cells instead of human thyrocytes, and 419 
only the cAMP pathway is investigated. The same observations about TNAb or low-420 
affinity TSAb/TBAb apply to 28.6% euthyroid NO-TD patients developing post-ALTZ 421 
TRAb; in the future they might remain positive with no long-term clinical consequences, 422 
or might develop late onset TD. 423 
TD post ALTZ is often delayed by several years and the ability to reliably predict 424 
those at risk would allow targeted monitoring and possibly early intervention or 425 
prevention. TPOAb are already known to identify subjects at risk, with 69% of 426 
individuals TPOAb+ at baseline developing TD. However, TPOAb testing only detects 427 
around 15% of all future cases of TD post-ALTZ (9). Our data suggests that custom-made 428 
TRAb testing in combination with TPOAb testing at baseline might increase this to 429 
predicting around 20% of hyperthyroid cases and 80% of hypothyroid cases. Interestingly, 430 
in 2 hypothyroid patients pre-ALTZ ihTRAb positivity was no longer detectable at the 431 
time of disease onset, suggesting that TRAb titres fluctuate over time and are not always 432 
detectable. Furthermore, in these cases they also might have become spontaneously 433 
negative, and destructive thyroiditis might represent the sole mechanism of 434 
hypothyroidism. 435 
The analysis of ihTRAb proved less valuable for predicting the disease course 436 
after the onset of TD than expected. For example, not all subjects who developed 437 
hypothyroidism or GD with fluctuating course had detectable TBAb. Several explanations 438 
are possible: i) non-optimal timing of time-point C, often several months after the disease 439 
onset and the commencing of anti-thyroid treatments, usually associated with TRAb titres 440 
decrease and negativization; ii) TSAb/TBAb levels might fluctuate over time, not being 441 
always positive at the same time; iii) TBAb might interact with the TSHR with a lower 442 
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affinity compared with TSAb, and therefore might be masked by TSAb coexistence in our 443 
biological assays. Similarly, TBAb false positive cases have been described due to the 444 
concomitant presence of TSAb; if TSAb act as weak agonists, they interfere with the 445 
bTSH in the TBAb assay resulting in a signal reduction. In general, TSAb/TBAb 446 
coexistence can be challenging to demonstrate due to their mutual interference, depending 447 
on relative concentrations, affinities and potencies, varying over time. Sometimes serum 448 
serial dilutions are needed to properly distinguish between the two TRAb populations 449 
(26).  450 
However our findings show that around 40% of hypothyroidism post ALTZ is 451 
TBAb mediated, as suggested in previous studies (9,10); this is nonetheless substantially 452 
higher than reports in spontaneous disease (around 10%) (16,21). By contrast, 91.7% 453 
(11/12) of hypothyroid subjects were TPOAb positive, consistent with TBAb negative 454 
hypothyroidism post-ALTZ still being autoimmune in the majority of cases, but perhaps 455 
cell-mediated. However, it was notable that autTRAb were detectable in many subjects 456 
who developed hypothyroidism or a switching course as well as all those with 457 
hyperthyroidism. Currently, autTRAb measurement is recommended only in patients 458 
developing hyperthyroidism; if our observations are confirmed in larger prospective 459 
studies, autTRAb testing should probably be extended to all cases of post-ALTZ TD, 460 
including hypothyroidism, since they appear to predict a more complex clinical course 461 
(i.e. possibility of thyroid function switching) requiring close observation.  462 
The strength of our study is the long follow-up to define outcome (≥ 5 years where no 463 
TD is reported) and the wide range of thyroid autoantibody assays used. However, ALTZ 464 
has only recently been licensed for use in relapsing/remitting MS (since 2014) and hence 465 
ALTZ-induced TD is currently not very common, especially cases with the long follow-466 
up required to define outcome. As a result, our cohort is relatively small (n=45) and this is 467 
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a limitation. Furthermore, due to the retrospective nature of the study, serum was not 468 
available at all time-points in the whole cohort, and in particular, samples at the time of 469 
TD onset were not always available. However we believe our finding that TRAb can 470 
precede disease onset and are associated with subsequent TD is robust as our numbers 471 
were consistent with our a priori power calculations. 472 
 473 
In conclusion we have observed that TRAb can precede TD by many years and, if 474 
present before ALTZ, can increase the risk of subsequent development of TD. Future 475 
prospective studies are needed to determine the exact value of baseline and follow-up 476 
TRAb testing in subjects treated with ALTZ and the most valuable assay to use. Such 477 
studies, as well as large cohort studies in spontaneous thyroid autoimmunity may also be 478 
used to investigate and define the process of affinity maturation in TRAb further. Now 479 
that ALTZ is licensed for the treatment of relapsing/remitting MS in more than 60 480 
countries, the available case load for prospective studies is likely to substantially increase 481 
and make at least the studies in ALTZ induced disease feasible.  482 
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FIGURES 678 
 679 
Figure 1: Serum time-points 680 
 681 
ALTZ: first alemtuzumab treatment. TD: patients developing thyroid dysfunction. NO-682 
TD: patients not developing thyroid dysfunction. 683 
A: first available time before ALTZ (both TD and NO-TD). B: post ALTZ, first available 684 
time before the onset of thyroid dysfunction (TD) or the latest available time post-ALTZ 685 
(NO-TD). C: post ALTZ during the onset of thyroid function abnormalities, or in 686 
alternative the earliest available time after it (TD only). 687 
 688 
Figure 2: ihTRAb positive results at all time-points689 
690 
  691 
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Cross-sectional results of all available sera at pre-specified time-points (see Figure 1) 692 
analysed with in-house assays to detect autoantibodies to the thyrotropin receptor 693 
(ihTRAb), obtained in patients developing thyroid dysfunction (TD) and patients not 694 
developing any thyroid dysfunction (NO-TD). Below the dashed line TD patients were 695 
further sub-grouped into hyperthyroidism (HYPER) or hypothyroidism (HYPO) as first 696 
clinical manifestation. Numbers in brackets indicate the total number of available sera for 697 
each time-point and patient subgroup.  698 
A: time-point A = before the first treatment with alemtuzumab (ALTZ). B: time-point B = 699 
latest available time post-ALTZ and before TD onset, when applicable. C: time-point C 700 
(TD only) = post ALTZ during the onset of thyroid function abnormalities, or in 701 
alternative the earliest available time after it. 702 
FC-TRAb (azure) = TRAb detected by flow cytometry. LB-TSAb (green) = Stimulating 703 
TRAb detected by luciferase bioassays. LB-TBAb (purple) = Blocking TRAb detected by 704 
luciferase bioassays. Tot ihTRAb (orange) = positive FC-TRAb and/or LB-TSAb and/or 705 
LB-TBAb; percentages refer to this column. Neg TRAb (white) = ihTRAb negative 706 
results with all the three FC, LB-TSAb and LB-TBAb techniques. 707 
 708 
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TABLES 709 
 710 
Table 1: Patients’ characteristics 711 
  TD 
NO-TD 
(n=14) 
  1st manifestation: 
Hyperthyroidism 
(n=19) 
1st manifestation: 
Hypothyroidism 
(n=12) 
Overall 
(n=31) 
Female: n (%) 15 (78.9%) 8 (66.7%) 23 (74.2%) 10 (71.4%) 
Age (years) at 1st ALTZ: mean (SD) 32.0 (7.2) 37.0 (10.6) 33.8 (8.9) 35.0 (9.5) 
Tot n ALTZ treatments received: mean (SD) 1.8 (0.7) 1 2.2 (1.0) 1 2.0 (0.8)1 2.8 (0.8) 2 
years from 1st ALTZ to TD onset:  
mean (SD), median (range) 
3.1 (2.2) 
2.0 (1.0-8.7) 
3.2 (2.1) 
3.0 (0.8-7.3) 
3.0 (1.9) 
2.7 (0.8-8.7) 
NA 
Time-point A3: median (range) 
days  
before 1st ALTZ 
171.5 
(26-700) 
141 
(0-418) 
162.0 
(0-700) 
121.5 
(0-375) 
Time-point B4: median (range) 
years  
after 1st ALTZ 
1.4 
(0.3-7.8) 
2.5 
(0.6-6.6) 
1.63 
(0.3-7.8) 
6.2 
(5.1-8.1) 
days  
before TD onset 
192.0 
(56-680) 
179 
(28-583) 
192.0 
(28-680) 
NA 
Time-point C5: median (range) 
years  
after 1st ALTZ 
3.1 
(1.3-8.8) 
3.4 
(0.8-9.0) 
3.1 
(0.8-9.0) 
NA 
days  
after TD onset 
89.0 
(0-794) 
82.5 
(0-829) 
89.0 
(0-829) 
NA 
 712 
ALTZ = alemtuzumab treatment. n = number. NA = Not Applicable. TD = thyroid dysfunction (abnormal thyroid hormones). TD onset = time of the 713 
first TD defined as persistent (i.e. detectable in consecutive blood tests at least 3 months apart) and/or significant (i.e. requiring to immediate start a 714 
thyroid treatment). 715 
Fisher exact test (gender distribution) and t-test (other variables) excluded significant differences between the groups, when comparable (p= ns). 716 
1= until TD onset  717 
2= until the end of observational period (time-point B) 718 
3= Time-point A serum was available in 10 hyperthyroid, 6 hypothyroid (16 overall TD) and 14 NO-TD patients. 719 
4= Time-point B serum was available in 17 hyperthyroid, 8 hypothyroid (25 overall TD) and 14 NO-TD patients. 720 
5= Time-point C serum was available in 17 hyperthyroid, 12 hypothyroid (29 overall TD) patients. 721 
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Table 2: Time-point A: Predictive value of baseline TRAb versus TPOAb 722 
 No of 
Patients 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPOAb 
TPOAb 
and/or TRAb 
H
Y
P
E
R
T
H
Y
R
O
ID
 
1       
1    NA   
2 
 
 
  NA   
6 
 
 
 
 
     
Tot: 10 
1/10 
(10%) 
0/10 
(0%) 
0/10 
(0%) 
1/7 
(14.3%) 
2/10 
(20%) 
2/10 
(20%) 
H
Y
P
O
T
H
Y
R
O
ID
 1    NA   
1       
1*    NA   
1*       
1       
1       
Tot: 6 
2/6 
(33.3%) 
1/6 
(16.7%) 
1/6 
(16.7%) 
0/4 
(0%) 
3/6 
(50%) 
5/6 
(83.3%) 
N
O
-T
D
 
4 
 
 
 
  NA   
10 
 
 
 
 
 
 
 
 
     
Tot: 14 
0/14 
(0%) 
0/14 
(0%) 
0/14 
(0%) 
0/10 
(0%) 
0/14 
(0%) 
0/14 
(0%) 
 723 
Cross-sectional results of all available sera at time-point A (before alemtuzumab treatment; see Figure 724 
1) for autoantibodies to the thyrotropin receptor (TRAb) and autoantibodies to thyroid peroxidase 725 
(TPOAb), obtained in patients developing subsequent hyperthyroidism or hypothyroidism as first 726 
clinical manifestation, and patients not developing any thyroid dysfunction (NO-TD) following 727 
alemtuzumab treatment.  728 
White cells = negative TRAb/TPOAb results. Colored squares represent positive results: azure = 729 
TRAb detected by flow cytometry (FC-TRAb); green = stimulating TRAb detected by luciferase 730 
bioassays (LB-TSAb); purple = blocking TRAb detected by luciferase bioassays (LB-TBAb); grey = 731 
TRAb detected by automated systems (Aut-TRAb); yellow = TPOAb (automated assay); red = TRAb 732 
(any test) and/or TPOAb. NA = Not Available. 733 
* Fluctuating Graves’ disease (GD) presenting hypothyroidism as first clinical manifestation. 734 
 735 
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Table 3: TRAb, TPOAb and TSH status in patients with positive in-house TRAb assays (ihTRAb+) 736 
 737 
Hyperthyroid patients (GD) 738 
 Time-point A: 
Pre-ALTZ 
Time-point B: 
Last euthyroid time 
Time-point C: 
Post thyroid dysfunction 
ID 
TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
Time α 
(d) 
TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
Time β 
(d) 
TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
8 1.05 0.332 0.99 -8.58 2.2 80A 159 1.34 0.452 0.98 -12.98 1.9 225A 238 < 0.01 0.302 1.38 8.56 >40 66 B 
4 1.86 0.151 1.12 -7.95 NA <2B 105 0.27 0.243 1.54 -4.72 <1 58A 35 < 0.01 0.571 4.24 3.52 >40 <2B 
5 0.96 0.282 0.92 -28.85 <1 <2A 418 1.01 0.492 1.12 -8.40 <1 NA 0 < 0.01 0.442 0.76 21.03 12.0 403B 
2 0.4 0.061 1.34 -22.75 NA <2B 387 ^ NA 1.00 -11.74 0.3 NA 166 # 0.491 0.92 16.26 38.0 352B 
6 1.02 0.182 0.87 -0.76 <1 18A 302 1.27 0.132 0.75 4.71 0.6 <2B 22 < 0.01 0.752 2.78 0.19 17.6 14B 
27 2.37 0.213 1.10 4.57 0.3 <2B NA NA NA NA NA NA NA 182 3.87 0.313 1.12 26.84 2.4 9B 
40 NA NA NA NA NA NA 334 0.86 0.285 1.65 -13.88 1.7 13A 37 < 0.01 0.535 3.96 -21.73 33.6 2B 
36 NA NA NA NA NA NA 680 1.45 0.065 1.46 -6.20 0.3 56A 0 < 0.01 0.655 3.04 -22.92 >40 22B 
38 NA NA NA NA NA NA 142 4.10 0.114 0.78 -48.12 0.5 36A 0 < 0.01 0.344 1.32 -77.57 6.9 124A 
41 NA NA NA NA NA NA 294 1.00 0.024 1.15 -43.97 <1 5B 177 < 0.01 0.874 2.97 48.78 >40 728A 
ID 2: missing TSH values for both time-points B (^) and C (#), so the closest TSH results are provided: 739 
^ previous TSH= 0.36 mU/L (233 days before); next TSH <0.02 mU/L (202 days after, during a transient subclinical hyperthyroidism phase lasted <3 months). 740 
# previous TSH <0.02 mU/L (166 days before, same day of thyroid dysfunction onset); next TSH= 17.81 mU/L (55 days after, during carbimazole treatment).  741 
 742 
Fluctuating GD 743 
 
 
Time-point A: 
Pre-ALTZ 
Time-point B: 
Last euthyroid time 
Time-point C: 
Post thyroid dysfunction 
ID 
TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
Time α 
(d) 
TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
Time β 
(d) 
TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
1 1.40 0.161 0.6 32.58 <1 26A 118 0.53 0.182 0.95 -20.00 <1 31A 829 1.76 0.381 2.46 -16.31 >40 491A 
35 2.14 0.234 0.88 8.98 <1 3B 583  0.234 1.19 -13.41 0.6 NA 0 159.68 0.764 3.34 38.02 >40 442B 
7 0.89 0.052 1.21 -5.97 <1 44A 441 0.34 0.092 1.02 4.57 NA <2B 196 69.25 0.682 3.46 11.93 >40 82B 
42 NA NA NA NA NA NA NA NA NA NA NA NA NA 197 52.15 0.784 2.16 40.90 >40 >1300A 
 TSH not available. Previous TSH = 1.96 mU/L (182 days before); next TSH = 159.68 mU/L (583 days after, corresponding to time-point C, same day of thyroid dysfunction 744 
onset). 745 
 746 
  747 
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Hypothyroid patients 748 
 
 
Time-point A: 
Pre-ALTZ 
Time-point B: 
Last euthyroid time 
Time-point C: 
Post thyroid dysfunction 
ID 
TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
Time α 
(d) 
TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
Time β 
(d) 
TSH  
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
15 2.34 0.261 0.72 -1.44 0.6 688A NA NA NA NA NA NA NA 0 6.58 0.101 1.10 15.79 NA 377A 
37 2.26 0.094 1.54 -31.97 NA 68A 337 NA 0.074 1.63 -9.95 NA NA 6 35.46 0.104 0.63 -12.25 <1 >1300A 
44 1.34 0.074 1.09 7.16 <1 21B NA NA NA NA NA NA NA 0 9.18 0.254 0.86 -6.08 NA 377B 
33 NA NA NA NA NA NA 28 0.18 0.875 2.33 66.27 NA >1300A 159 5.39 0.685 1.21 21.56 >40 >1300A 
31 NA NA NA NA NA NA 203 1.49 0.105 1.26 -7.90 0.8 672A 672         * 0.085 0.94 2.44 NA >1000B 
29 NA NA NA NA NA NA 210 1.34 0.245 1.17 -27.18 0.5 37A 224 5.26 0.905 1.21 53.82 >40 496A 
32 NA NA NA NA NA NA NA NA NA NA NA NA NA 0 80.42 0.785 0.99 -11.59 20.7 >1300A 
* TSH not available, but likely within the normal range, considering the evidence of stable euthyroidism under levothyroxine treatment for nearly 4 years post-ALTZ.  749 
 750 
NO-TD patients 751 
 Time-point A: 
Pre-ALTZ 
Time-point B: 
Latest time post-ALTZ 
ID TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
TSH 
(mU/L) 
FC 
TRAb 
LB 
TSAb 
LB 
TBAb 
Aut 
TRAb 
TPO 
Ab 
13 1.63 0.151 1.13 13.88 0.85 <10A 1.84 0.051 1.03 30.92 0.3 <2B 
25 1.30 0.233 0.82 8.99 <1 <2B 0.90 0.193 1.15 26.62 <0.9 <2B 
17 0.82 0.212 1.04 0.58 <1 <2B 1.54 0.392 1.08 -2.39 <0.9 <2B 
19 1.22 0.255 0.75 -2.13 NA <2B ★ 0.33
5 0.88 -1.84 <0.9 <2B 
★ TSH not available, but likely within the normal range, considering the evidence of stable euthyroidism for 5.9 years post-ALTZ.  752 
 753 
Summary of autoantibodies to the thyrotropin receptor (TRAb), autoantibodies to thyroid peroxidase (TPOAb) and thyroid 754 
stimulating hormone (TSH) status among patients positive for in-house TRAb assays (ihTRAb+). Only patients resulted ihTRAb+ in 755 
at least one time-point are represented.  756 
White cells = negative TRAb/TPOAb results. Colored squares represent positive results: azure = TRAb detected by flow cytometry 757 
(FC-TRAb); green = stimulating TRAb detected by luciferase bioassays (LB-TSAb); purple = blocking TRAb detected by luciferase 758 
bioassays (LB-TBAb); grey = TRAb detected by automated systems (AutTRAb); yellow = TPOAb (automated assay).  759 
ALTZ = Alemtuzumab. GD = Graves’ disease. ID = patient’s identification number. NA = Not Applicable or Not Available. 760 
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TSH normal reference range varies between 0.30 – 4.4 mU/L and 0.35 – 5.5 mU/L, depending on the assay used and the date of test 761 
(see supplemental table 1). 762 
α = Time (days) before onset of thyroid dysfunction  763 
β = Time (days) after onset of thyroid dysfunction  764 
Reference Ranges and Positivity Cut-offs 765 
AutTRAb (IU/L) reference ranges: negative <1, borderline 1–1.5, positive >1.5 (until January 2014); negative <0.9, borderline 766 
0.9–1.6, positive (from February 2014 onwards) 767 
A,B = TPOAb (U/ml) reference ranges: A = negative <60, positive ≥60 (until May 2010); B = negative <6, positive ≥6 (from 768 
June 2010 onwards) 769 
FC-TRAb positivity cut-offs. Samples have been tested in 5 different sets of experiments, each producing slightly different 770 
mean of greatest differences in fluorescence intensity between the two histograms (D) and relative standard deviation (SD) among 771 
pooled controls. Samples were considered positive if Dsample > Dcontrols + 2 SD. 772 
1 = Set 1 Dcontrols + 2 SD = 0.26 773 
2 = Set 2 Dcontrols + 2 SD = 0.30 774 
3 = Set 3 Dcontrols + 2 SD = 0.42 775 
4 = Set 4 Dcontrols + 2 SD = 0.21 776 
5 = Set 5 Dcontrols + 2 SD = 0.32 777 
LB-TSAb positive if stimulation index (SI) >1.5.  778 
LB-TBAb (%) positive if inhibition index (InI) >20%. 779 
 780 
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SUPPLEMENTAL MATERIAL 781 
Supplemental Table 1: Automated Laboratory Assays and Reference Ranges for TPOAb, FT4, FT3 and TSH 782 
 783 
TIME PERIOD ASSAY REFERENCE RANGES 
TPOAb (U/mL) TSH (mU/L) FT4 (pmol/L) FT3 (pmol/L) 
From 1/1/2006  
To 31/5/2010 
Siemens ADVIA 
Centaur 
<60 0.35 – 5.5 10.0 – 25.0 (from 1/1/2006) 
9.8 – 23.1 (from 21/5/2009) 
3.5 – 6.5 
From 01/06/2010 
To current 
Abbott Architect <6 0.30 – 4.40 
0.35 – 5.0 (from 29/6/10) 
0.30 – 4.4 (from 31/1/2014) 
9.0 – 19.1 
9.2 – 21.0 (from  31/1/2014) 
9.0 – 19.1 (from 5/11/2014) 
2.6 – 5.7 
 784 
TSH = thyroid stimulating hormone. FT4 = free-thyroxine. FT3 = free-triiodothyronine. 785 
 786 
 787 
Supplemental Table 2: TRAb and TPOAb predictive values, sensitivity and specificity at time-point A 788 
 789 
  Sensitivity PPV Specificity NPV 
TD 
versus 
NO-TD 
ihTRAb 5/16 (31.2%) 5/5 (100%) 14/14 (100%) 14/25 (56.0%) 
TPOAb 5/16 (31.2%) 5/5 (100%) 14/14 (100%) 14/25 (56.0%) 
ihTRAb and/or TPOAb 7/16 (43.8%) 7/7 (100%) 14/14 (100%) 14/23 (60.9%) 
HYPER 
versus 
NO-TD 
ihTRAb 1/10 (10.0%) 1/1 (100%) 14/14 (100%) 14/23 (60.9%) 
TPOAb 2/10 (20.0%) 2/2 (100%) 14/14 (100%) 14/22 (63.6%) 
ihTRAb and/or TPOAb 2/10 (20.0%) 2/2 (100%) 14/14 (100%) 14/22 (63.6%) 
HYPO 
versus 
NO-TD 
ihTRAb 4/6 (66.7%) 4/4 (100%) 14/14 (100%) 14/16 (87.5%) 
TPOAb 2/10 (50.0%) 3/3 (100%) 14/14 (100%) 14/17 (82.3%) 
ihTRAb and/or TPOAb 5/6 (83.3%) 5/5 (100%) 14/14 (100%) 14/15 (93.3%) 
 790 
TD = thyroid dysfunction; NO-TD = absence of thyroid dysfunction; HYPER = hyperthyroidism; HYPO = hypothyroidism; ihTRAb = 791 
TRAb measured with in-house assays; PPV = positive predictive value; NPV = negative predictive value. 792 
 793 
 794 
 795 
